Crossmark

Introduction of a hexavalent vaccine containing acellular pertussis into the national immunization program for infants in Peru: a cost-consequence analysis of vaccination coverage

Crossref DOI link: https://doi.org/10.1186/s12913-024-11684-8

Published Online: 2024-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Seinfeld, Janice

Sobrevilla, Alfredo

Rosales, María Laura

Ibañez, Mauricio

Munayco, César

Ruiz, Delia
Funding

Funding for this research was provided by:

Sanofi
License Information

Text and Data Mining valid from 2024-10-10

Version of Record valid from 2024-10-10
More Information

Article History

Received: 17 May 2024

Accepted: 30 September 2024

First Online: 10 October 2024

Declarations

:

: The data used for the study is publicly available and therefore ethics approval was not required.

: Not applicable.

: All authors are employees of Videnza Consultores who were contracted by Sanofi to conduct this research.

Document is current

Any future updates will be listed below